| 1. |
- Patel, Riyaz S., et al.
(författare)
-
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events : A GENIUS-CHD Study of Individual Participant Data
- 2019
-
Ingår i: Circulation. - 2574-8300. ; 12:4
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk.METHODS: A variant at chromosome 9p21 (rs1333049) was tested for association with subsequent events during follow-up in 103 357 Europeans with established CHD at baseline from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% male, mean age 62.9 years). The primary outcome, subsequent CHD death or myocardial infarction (CHD death/myocardial infarction), occurred in 13 040 of the 93 115 participants with available outcome data. Effect estimates were compared with case/control risk obtained from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) including 47 222 CHD cases and 122 264 controls free of CHD.RESULTS: Meta-analyses revealed no significant association between chromosome 9p21 and the primary outcome of CHD death/myocardial infarction among those with established CHD at baseline (GENIUSCHD odds ratio, 1.02; 95% CI, 0.99-1.05). This contrasted with a strong association in CARDIoGRAMPlusC4D odds ratio 1.20; 95% CI, 1.18-1.22; P for interaction < 0.001 compared with the GENIUS-CHD estimate. Similarly, no clear associations were identified for additional subsequent outcomes, including all-cause death, although we found a modest positive association between chromosome 9p21 and subsequent revascularization (odds ratio, 1.07; 95% CI, 1.04-1.09).CONCLUSIONS: In contrast to studies comparing individuals with CHD to disease-free controls, we found no clear association between genetic variation at chromosome 9p21 and risk of subsequent acute CHD events when all individuals had CHD at baseline. However, the association with subsequent revascularization may support the postulated mechanism of chromosome 9p21 for promoting atheroma development.
|
|
| 2. |
|
|
| 3. |
- Patel, Riyaz S., et al.
(författare)
-
Subsequent Event Risk in Individuals With Established Coronary Heart Disease : Design and Rationale of the GENIUS-CHD Consortium
- 2019
-
Ingår i: Circulation. - 2574-8300. ; 12:4
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD.METHODS: The consortium currently includes 57 studies from 18 countries, recruiting 185 614 participants with either acute coronary syndrome, stable CHD, or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events.RESULTS: Enrollment into the individual studies took place between 1985 to present day with a duration of follow-up ranging from 9 months to 15 years. Within each study, participants with CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, using a federated analysis approach, yielded expected associations between age (hazard ratio, 1.15; 95% CI, 1.14-1.16) per 5-year increase, male sex (hazard ratio, 1.17; 95% CI, 1.13-1.21) and smoking (hazard ratio, 1.43; 95% CI, 1.35-1.51) with risk of subsequent CHD death or myocardial infarction and differing associations with other individual and composite cardiovascular endpoints.CONCLUSIONS: GENIUS-CHD is a global collaboration seeking to elucidate genetic and nongenetic determinants of subsequent event risk in individuals with established CHD, to improve residual risk prediction and identify novel drug targets for secondary prevention. Initial analyses demonstrate the feasibility and reliability of a federated analysis approach. The consortium now plans to initiate and test novel hypotheses as well as supporting replication and validation analyses for other investigators.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Zewinger, Stephen, et al.
(författare)
-
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease : a molecular and genetic association study
- 2017
-
Ingår i: The Lancet Diabetes and Endocrinology. - : ELSEVIER SCIENCE INC. - 2213-8587 .- 2213-8595. ; 5:7, s. 534-543
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in patients with established coronary heart disease remains less clear.Methods: We obtained data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We tested associations of tertiles of lipoprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and with severity of disease by generalised linear modelling, with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Results for plasma lipoprotein(a) concentrations were validated in five independent studies involving 10 195 patients with established coronary heart disease. Results for genetic associations were replicated through large-scale collaborative analysis in the GENIUS-CHD consortium, comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts.Findings: The median follow-up was 9.9 years. Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest tertile (adjusted hazard radio [HR] 1.44, 95% CI 1.14-1.83) and the presence of either LPA SNP (1.88, 1.40-2.53). No associations were found in LURIC with all-cause mortality (highest tertile of lipoprotein(a) concentration in plasma 0.95, 0.81-1.11 and either LPA SNP 1.10, 0.92-1.31) or cardiovascular mortality (0.99, 0.81-1.2 and 1.13, 0.90-1.40, respectively) or in the validation studies.Interpretation: In patients with prevalent coronary heart disease, lipoprotein(a) concentrations and genetic variants showed no associations with mortality. We conclude that these variables are not useful risk factors to measure to predict progression to death after coronary heart disease is established.
|
|
| 7. |
- Khodorkovskii, M. A., et al.
(författare)
-
Multiphoton mass spectra of Xe-2 molecules in the range of excited Xe*(6p, 5d) atoms
- 2006
-
Ingår i: Optics and Spectroscopy. ; 100:4, s. 497-509
-
Tidskriftsartikel (refereegranskat)abstract
- The (2 + 1) photoionization mass spectra of Xe-2 molecules are studied in a supersonic jet upon excitation by laser radiation in the energy range 80321.3-77821 cm(-1), corresponding to the dissociation of the Xe-2 molecule into atoms Xe(S-1(0)) + Xe*(6p, 5d). Several vibrational progressions are observed, which are attributed to two-photon transitions of Xe-2 from the ground state to the excited states of the 0(g)(+), 1(g), and 2(g) symmetries. Based on the analysis of these progressions, the molecular constants of a number of excited states of Xe? are estimated.
|
|
| 8. |
- Khodorkovskii, M. A., et al.
(författare)
-
Multiphoton mass spectra of XeKr molecules in the range of excited Xe*6p[5/2](2,3) atoms
- 2007
-
Ingår i: Optics and Spectroscopy. - 0030-400X .- 1562-6911. ; 102:6, s. 834-841
-
Tidskriftsartikel (refereegranskat)abstract
- Data on excited states of XeKr molecules in the energy range 78280-77600 cm(-1) are obtained. Using the method of multiphoton laser photoionization of molecules in a supersonic jet, five vibrational progressions of XeKr molecules are obtained, which are attributed to five electronic-vibrational transitions from the ground state of the XeKr molecule of the symmetry 0(+) to excited states of the symmetry Omega = 0(+), 1, 2 with the dissociation limit (KrS0)-S-1 + Xe*6p[5/2](2) and of the symmetry Omega = 1, 2 with the dissociation limit Kr + Xe*6p[5/2](3). The molecular constants of the corresponding excited states of the XeKr molecule are estimated.
|
|
| 9. |
- Khodorkovskii, M. A., et al.
(författare)
-
Study of the lowest electronic states of Xe-2, XeKr, and XeAr molecules by the method of multiphoton resonance ionization
- 2008
-
Ingår i: Optics and Spectroscopy. - 0030-400X .- 1562-6911. ; 104:5, s. 674-685
-
Tidskriftsartikel (refereegranskat)abstract
- The spectra of Xe-2, XeKr, and XeAr molecules in the range 66 500-68 800 cm(-1) are obtained by the methods of (2 + n) and (3 + n) (n = 1, 2, 3) resonance multiphoton ionization during the registration of molecular and atomic ions. The combining of two-and three-photon resonance excitations of Xe-2 molecules makes it possible to obtain the spectra caused by transitions from the ground state X0(g)(+) to the excited states of Xe*6s[3/2](1,2)degrees(XeS0)-S-1 molecules both of the even (0(g)(+), 1(g) ) and of the odd (B0(u)(+), B'1(u) , 2(u) ) symmetries. The data on the Omega = 2(u) state of the Xe-2 molecule with the dissociation limit Xe*6s[3/2](2)degrees + (XeS0)-S-1 and on the Omega = 1 state of the XeAr molecule with the dissociation limit Xe*6s[3/2](1)degrees (ArS0)-S-1 are obtained for the first time. The potential curve of the excited 2(u) state of the Xe*6s[3/2](2)degrees (XeS0)-S-1 molecule is repulsive and intersects the potential curve of the B0(u) + state of the Xe*6s[3/2](1)degrees (XeS0)-S-1 molecule. In the case of the three-photon excitation, it is observed that all the bands in the spectra of XeKr and XeAr molecules are broadened and are shifted, which indicates that, in an intense light field, the influence of the dynamic Stark effect is significant.
|
|
| 10. |
- Nelson, C. P., et al.
(författare)
-
Genetically Determined Height and Coronary Artery Disease
- 2015
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 372:17, s. 1608-1618
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND The nature and underlying mechanisms of an inverse association between adult height and the risk of coronary artery disease (CAD) are unclear.METHODS We used a genetic approach to investigate the association between height and CAD, using 180 height-associated genetic variants. We tested the association between a change in genetically determined height of 1 SD (6.5 cm) with the risk of CAD in 65,066 cases and 128,383 controls. Using individual-level genotype data from 18,249 persons, we also examined the risk of CAD associated with the presence of various numbers of height-associated alleles. To identify putative mechanisms, we analyzed whether genetically determined height was associated with known cardiovascular risk factors and performed a pathway analysis of the height-associated genes.RESULTS We observed a relative increase of 13.5% (95% confidence interval [CI], 5.4 to 22.1; P<0.001) in the risk of CAD per 1-SD decrease in genetically determined height. There was a graded relationship between the presence of an increased number of height-raising variants and a reduced risk of CAD (odds ratio for height quar-tile 4 versus quartile 1, 0.74; 95% CI, 0.68 to 0.84; P<0.001). Of the 12 risk factors that we studied, we observed significant associations only with levels of low-density lipoprotein cholesterol and triglycerides (accounting for approximately 30% of the association). We identified several overlapping pathways involving genes associated with both development and atherosclerosis.CONCLUSIONS There is a primary association between a genetically determined shorter height and an increased risk of CAD, a link that is partly explained by the association between shorter height and an adverse lipid profile. Shared biologic processes that determine achieved height and the development of atherosclerosis may explain some of the association.
|
|
